Pathogenic variants in COL18A1, UFSP2, ZFYVE26, and ATP13A2 contribute to a wide range of clinical phenotypes, from ASM-resistant epilepsy and developmental delay to ataxia, intellectual disability, speech impediment, and other associated symptoms. This evidence concerns the gene ATP13A2 and Ataxia.